Related links
Postmarketing Drug Safety and Inspection Readiness
Jun 19, 2018 Once a drug is approved, applicant holders MUST receive, evaluate, and report all adverse drug experiences (ADEs) to FDA, even if the drug is
Learn more
Guidance for Industry
The. 133 new postmarketing periodic safety reporting proposals will be based on recommendations. 134 in the ICH guidance E2C Clinical Safety Data Management:
Learn more
Postmarketing Safety Reporting for Human Drug and
Jan 29, 2020 Draft Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines, CBER, Biologics.
Learn more